Oesophago-Gastric Cancer | ATTAX 3
An advanced oesophago-gastric cancer with weekly docetaxel, cisplatin, fluoropyrimidine (w/TCF) plus or minus panitumumab in advanced oesophago-gastric cancer.
Schema
Summary
The ATTAX3 study is a randomised, phase II study comprising two separate components. Patients with advanced oesophago-gastric cancer will be randomised to receive chemotherapy only (wTCF/X) or chemotherapy plus panitumumab. The study will evaluate the objective tumour response rate of these treatment regimes.
